Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement - Summary - MDSpire

Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement

  • By

  • Kristine A. Karvonen

  • Jean A. McDougall

  • Elizabeth A. Carosso

  • Tina Burrows

  • Solange H. Mecham

  • Chongzhi Di

  • Sarah D. Hohl

  • Elizabeth Stohr

  • Anne Devine

  • Hannah Linden

  • Ajay K. Gopal

  • Evan Y. Yu

  • Andrew J. Cowan

  • Jason A. Mendoza

  • June 16, 2026

  • 0 min

Share

Objective:

To evaluate the feasibility, acceptability, implementation outcomes, and preliminary efficacy of the GUIDE clinical trial navigation program.

Approach:
    Key Findings:
    • Disparities in clinical trial participation exist among socioeconomically disadvantaged populations.
    • Clinical trial navigation programs may improve access but lack well-defined components.
    • GUIDE aims to address these gaps by combining navigation support with financial reimbursement, potentially enhancing patient trust and health-related quality of life.
    Interpretation:

    The GUIDE program is designed to enhance clinical trial enrollment and retention while addressing health-related social needs and financial burdens through comprehensive support.

    Limitations:
    • The study is limited to a single cancer center and may not be generalizable to other settings.
    • The sample size of 100 patients may limit the statistical power of the findings.
    • The lack of diversity in the sample may affect the generalizability of the results.
    Conclusion:

    The GUIDE program represents a novel approach to improving access to cancer clinical trials, with a focus on both navigation and financial support.

    Sources:

Original Source(s)

Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement

  • by Kristine A. Karvonen, Jean A. McDougall, Elizabeth A. Carosso, Tina Burrows, Solange H. Mecham, Chongzhi Di, Sarah D. Hohl, Elizabeth Stohr, Anne Devine, Hannah Linden, Ajay K. Gopal, Evan Y. Yu, Andrew J. Cowan, Jason A. Mendoza

  • June 16, 2026

Related Content

Autophagy modulation in gynaecologic oncology: insights into immune regulation and therapeutic potential

Clinicopathologic features and integrated outcome analysis of pediatric and young adult salivary secretory carcinoma

Who Decides How AI Enters Pathology?

Liron Pantanowitz explains why validation, leadership, and real-world use matter more than performance metrics